GYNECOLOGIC CANCER: Edited by Gottfried E. KonecnyUpdate in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical researchWashington, Christina; Gunderson, Camille C.; Moore, Kathleen N.Author Information Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Correspondence to Kathleen N. Moore, MD, Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA. Tel: +1 405 271 7770; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology: February 2019 - Volume 31 - Issue 1 - p 4-11 doi: 10.1097/GCO.0000000000000507 Buy Metrics Abstract Purpose of review This review will provide an update of recently presented clinical data as well as discuss ongoing trials focused on the incorporation of poly (ADP-ribose) polymerase inhibitors (PARPi) into the treatment paradigm for ovarian cancer. Recent findings As of this publication, PARPi have indications in many parts of the globe as maintenance therapy following response to platinum-based chemotherapy in the setting of platinum-sensitive recurrence. In addition, in the United States, two PARPi have indications as monotherapy treatment for recurrent ovarian cancer in patients with a BRCA mutation and at least two prior lines of therapy. Exciting data was published in October 2018, demonstrating an unprecedented benefit to utilization of olaparib following response to front-line platinum-based chemotherapy among patients with a BRCA mutation and this data is expected to expand the indication for olaparib globally. Summary Ongoing studies will seek to expand the benefit of PARPi beyond the BRCA population in front-line therapy as well as to overcome inherent and acquired resistance to PARPi with studies of novel combinations with antiangiogenesis agents, immune-oncology agents and chemotherapy. These efforts may identify more settings and populations in which PARPi provide clinical benefit. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.